<unk> , sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of<unk>  is done intravenously. Each intravenous injection of<unk>  should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie. Common side effects of<unk>  with lenalidomide and dexamethasone includes fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, and pneumonia. The most common side effects of<unk>  with pomalidomide and dexamethasone includes constipation and hyperglycemia. There is no available information for the use of<unk>  in pregnant women.<unk>  is an immunostimulatory antibody that targets the Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) through two mechanisms. In May 2014, it was granted breakthrough therapy designation by the US Food and Drug Administration (FDA) (for multiple myeloma). The initial FDA approval of<unk>  in 2015 in combination with lenalidomide and dexamethasone was carried out through the results illustrated in the ELOQUENT 2 study. In May 2016 the EC/EU gave a similar approval. Furthermore, the results of the ELOQUENT 3 study led to the FDA approval of<unk>  in combination with pomalidomide and dexamethasone in 2018.
Elotuzumab
Pertuzumab
Idarucizumab
Gatipotuzumab
Theralizumab
Alemtuzumab
Etaracizumab
Risankizumab